Signal Genetics Announces Master Service Agreement With Major Biopharmaceutical Partner

Go back to Signal Genetics Announces Master Service Agreement With Major Biopharmaceutical Partner

Signal Genetics (SGNL) Signs Second MSA with for MyPRS; Success Could Lead to Larger Phase 3s

September 23, 2015 2:40 PM EDT

Chardan Capital affirms its Buy rating and $2.75 price target on Signal Genetics (Nasdaq: SGNL) after the company announced the signing of a... More